Drug Approval | May 25, 2026
Datroway wins US nod in aggressive breast cancer subtype
Clearance marks major shift beyond chemotherapy
Clearance marks major shift beyond chemotherapy
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Transition to a fermentation-based globally integrated CDMO platform
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Subscribe To Our Newsletter & Stay Updated
